Erwin Brenndörfer has joined LIDDS as Project Manager Translational Medicine and will be responsible for managing LIDDS growing portfolio of pre-clinical studies as well as continuing the development of the NanoZolid® technology and identifying new drugs that can be combined with NanoZolid®.
Erwin Brenndörfer has extensive experience in managing pre-clinical oncology studies gained during his time as a project leader for pre-clinical drug development at Medivir. Erwin will be working in the pre-clinial R&D team led by Martin Johansson.
Erwin has a PhD from Heinrich Heine University in Düsseldorf, Germany, and after completing his studies Erwin worked at Karolinska Institutet where he was an Assistant Professor of Infectious Diseases.
-We are very excited that Erwin has joined the LIDDS team. Our growing portfolio of pre-clinical projects means we also need to continue to grow and strengthen our organization. Erwin’s experience and expertise are a great fit for LIDDS and he is a valuable addition to the LIDDS team, says Monica Wallter, CEO of LIDDS.
-LIDDS is an exciting company with a great team of people. I see a lot of potential in the NanoZolid® technology and I’m looking forward to using my skills and expertise to further develop LIDDS and the NanoZolid® technology, says Erwin Brenndörfer.
Erwin has been published more than 20 times in scientific publications, mainly on the Hepatitis C virus, and has been a frequent speaker at scientific conferences.
You can see an interview with Erwin at LIDDS LinkedIn page where he speaks about his role and what makes LIDDS and NanoZolid® so exciting: https://www.linkedin.com/company/lidds/
For additional information, please contact:
Monica Wallter, CEO, LIDDS +46 (0)737 07 09 22 email@example.com
About LIDDS AB (publ)
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid® is clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid® is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares (LIDDS) are listed on Nasdaq First North. Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com